Sionna Therapeutics, Inc. (SION)
| Market Cap | 174.97M -89.9% |
| Revenue (ttm) | n/a |
| Net Income | -97.38M |
| EPS | -2.17 |
| Shares Out | 45.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000,698 |
| Open | 3.680 |
| Previous Close | 3.690 |
| Day's Range | 3.630 - 3.905 |
| 52-Week Range | 3.550 - 54.970 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | 21.00 (+442.64%) |
| Est. Earnings | Nov 9, 2026 |
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for SION stock is "Hold." The 12-month stock price target is $21.0, which is an increase of 442.64% from the latest price.
News
Sionna Therapeutics to present at 2026 North American Cystic Fibrosis Conference
Sionna Therapeutics (SION) “announced data being presented at the 2026 North American Cystic Fibrosis Conference (NACFC) being held in Atlanta, Georgia on October 7-10, 2026. The oral presentation by ...
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 s...
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
Sionna Therapeutics price target raised to $6 from $5 at Wedbush
Wedbush raised the firm’s price target on Sionna Therapeutics (SION) to $6 from $5 and keeps a Neutral rating on the shares. The firm notes the company released additional post…
Sionna Therapeutics Transcript: Study update
Post hoc analysis of the PreciSION CF Phase IIa trial revealed confounding due to non-adherence and lower Trikafta exposures, supporting a shift to a dual combination strategy with SION-451 plus SION-2222. The AscenSION CF phase IIa trial will begin in Q1 2027 to evaluate this approach.
Sionna Therapeutics Press release: Study update
Sionna Therapeutics issued a press release on September 14, 2026, disclosing material business information to investors.
Sionna Therapeutics Slides: Study update
Sionna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Sionna Therapeutics to advance SION-451 + SION-2222 into AscenSION CF POC trial
Sionna Therapeutics (SION) announced plans to advance SION-451 + SION-2222, its preferred proprietary dual combination, into the AscenSION CF Phase 2a proof-of-concept, or POC, trial, and results from...
Sionna Therapeutics to reduce workforce by 46%
Following the completion of a comprehensive review of its operations, Sionna’s board of directors has approved a workforce reduction of approximately 46% and the company has implemented other cost-sav...
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics
SAN DIEGO, Aug. 19, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and direc...
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information
SAN DIEGO--(BUSINESS WIRE)---- $SION #Health--Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and ...
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $SION--SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law.
SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics
Sionna Therapeutics shares traded above $44 in July 2026; after the SION-719 Phase 2a readout, roughly 90% of that value was lost. SueWallSt notifies investors of a pending investigation into potentia...
Sionna Therapeutics rises 15.9%
Sionna Therapeutics (SION) is up 15.9%, or 71c to $5.21.
Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results—Johnson Fistel Investigates
SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating potential violations of the federal securities laws involving Sionna Therapeu...
Sionna Therapeutics price target lowered to $5 from $38 at Freedom Broker
Freedom Broker analyst Ilya Zubkov lowered the firm’s price target on Sionna Therapeutics (SION) to $5 from $38 and keeps a Hold rating on the shares, telling investors that the…
Sionna Therapeutics rises 14.0%
Sionna Therapeutics (SION) is up 14.0%, or 63c to $5.13.
Sionna Therapeutics downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded Sionna Therapeutics (SION) to Hold from Buy after SION-719 failed to show meaningful sweat chloride reduction in the Phase 2a PreciSION-CF trial. Following today’s update, the...
Sionna Therapeutics downgraded to Neutral from Buy at BTIG
BTIG downgraded Sionna Therapeutics (SION) to Neutral from Buy with no price target after the PreciSION CF trial did not meet its key activity endpoint. With SION-719 discontinued, the NBD1…
Sionna Therapeutics downgraded to Market Perform from Outperform at LifeSci Capital
LifeSci Capital downgraded Sionna Therapeutics (SION) to Market Perform from Outperform with a $6 price target
Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss
As previously reported, Guggenheim downgraded Sionna Therapeutics (SION) to Neutral from Buy and removed the firm’s prior price target after a study of Sionna’s NBD1 stabilizer combined with Vertex Ph...
Sionna Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Yatin Suneja downgraded Sionna Therapeutics (SION) to Neutral from Buy.
Citizens downgrades Sionna Therapeutics as SION-719 miss questions NBD1 thesis
As previously reported, Citizens downgraded Sionna Therapeutics (SION) to Market Perform from Outperform after SION-719 missed in the Phase 2a PreciSION CF study. Management is discontinuing SION-719 ...
Sionna Therapeutics falls -92.0%
Sionna Therapeutics (SION) is down -92.0%, or -$46.94 to $4.10.